Destiny Pharma today announced its interim results for the 6 months ended 30 June 2021

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)
Interim results for the six months ended 30 June 2021
Primary endpoint met in XF-73 Phase 2b clinical trial
Secondary endpoint analysis showed XF-73 exhibited a significant and
sustained nasal reduction of S. aureus
Discussions progressing on XF-73 nasal Phase 3 study design
Good progress for NTCD-M3 programme targeting C. difficile infection recurrence: Phase 3 on track to start in H2 2022
Positive market research report underlines market opportunity for NTCD-M3 in US and Europe
Company funded through to Q4 2022
Brighton, United Kingdom – 9 September 2021 – Destiny Pharma (AIM: DEST), a clinical stage, innovative biotechnology company
focused on the development of novel medicines to prevent life threatening infections, announces its unaudited interim financial results for
the half-year ended 30 June 2021 and an update for the year to date.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...